Abstract P68 Table 1

Spearman’s Rho correlation between asthma-related symptoms and other patient-reported outcomes and FEV1 at baseline and end of treatment

Variables For CorrelationBaselineChange From Baseline to End of Treatment
BenralizumabPlaceboBenralizumabPlacebo
Daily diary assessments
Activity function: Limitation of activities0.770.760.730.66
Activity function: Avoidance of activities0.760.730.720.67
Activity function: Need to pace self0.760.720.710.66
Feeling tired0.760.720.700.66
Feeling stressed0.500.480.490.36
Percentage of night-time awakening0.650.620.480.45
Total rescue medication use (puffs per day)0.570.560.510.49
ACQ-6 score0.680.680.640.58
AQLQ(S)+12
Overall−0.60−0.55−0.61−0.52
Symptoms−0.62−0.59−0.61−0.53
Activity limitation−0.54−0.50−0.55−0.48
Emotional function−0.47−0.44−0.54−0.41
Environmental stimulation−0.37−0.33−0.42−0.35
Pre-bronchodilator FEV1 (L)−0.09−0.08−0.21−0.13
  • ACQ-6, Asthma Control Questionnaire, 6-question version; AQLQ(S)+12, Standardised Asthma Quality of Life Questionnaire for patients 12 years and older; FEV1, forced expiratory volume in 1 s. All p<0.05